GLP-1 RAs Improve Glycemic, Weight Outcomes in Pediatric Obesity, Diabetes
GLP-1 RA use was associated with improved cardiometabolic outcomes among pediatric patients with type 2 diabetes and obesity.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with improved glycemic control, weight, and cardiometabolic outcomes without affecting rates of depression, suicidal ideation, or behaviors among children and adolescents with obesity, prediabetes, or type 2 diabetes (T2D), according to study results published in JAMA Pediatrics.
Researchers conducted a systematic review and meta-analysis of 3 databases through February 28, 2025, to identify randomized controlled trials (RCTs) of FDA-approved GLP-1 RAs among individuals younger than 18 years of age.
Eligible trials compared GLP-1 RAs with placebo, with or without lifestyle modification, and reported both efficacy and safety outcomes.
No direct quotes available in the provided text.
Author's summary: GLP-1 RAs improve outcomes in pediatric obesity and diabetes.
More News
- Wallingford deli asks for help to keep feeding people in need
- Landmark New Report Shows Canadian Lobbyists Represent Major Polluters Alongside Environmental Groups
- Liam Hemsworth vs. Gabriella Brooks: Who Has the Higher Net Worth?
- Key Asks from Government – As Staffordshire Finalises LGR Submission - Staffordshire County Council Newsroom
- Why Hiring a Fishers Personal Injury Lawyer Is Key After a Car Accident, Slip, or Dog Bite | NorthPennNow
- Philippines economy to grow 5.6% in 2025 – Fitch
- Biopic reintroduces female revolutionary hero - BusinessWorld Online
- The environmental impact of the 2026 World Cup
- Why Experienced Lawyers Matter in a Personal Injury Case | NorthPennNow
- Jensen Ackles back on 'Tracker' 3.2 to amp up the suspense